A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques

Can administration of a prostaglandin (PG) E2 receptor 2 (PTGER2) antagonist prevent pregnancy in adult female monkeys by blocking periovulatory events in the follicle without altering menstrual cyclicity or general health? This is the first study to demonstrate that a PTGER2 antagonist can serve as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human reproduction (Oxford) 2014-07, Vol.29 (7), p.1400-1412
Hauptverfasser: Peluffo, M C, Stanley, J, Braeuer, N, Rotgeri, A, Fritzemeier, K-H, Fuhrmann, U, Buchmann, B, Adevai, T, Murphy, M J, Zelinski, M B, Lindenthal, B, Hennebold, J D, Stouffer, R L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1412
container_issue 7
container_start_page 1400
container_title Human reproduction (Oxford)
container_volume 29
creator Peluffo, M C
Stanley, J
Braeuer, N
Rotgeri, A
Fritzemeier, K-H
Fuhrmann, U
Buchmann, B
Adevai, T
Murphy, M J
Zelinski, M B
Lindenthal, B
Hennebold, J D
Stouffer, R L
description Can administration of a prostaglandin (PG) E2 receptor 2 (PTGER2) antagonist prevent pregnancy in adult female monkeys by blocking periovulatory events in the follicle without altering menstrual cyclicity or general health? This is the first study to demonstrate that a PTGER2 antagonist can serve as an effective non-hormonal contraceptive in primates. The requirement for PGE2 in ovulation and the release of an oocyte surrounded by expanded cumulus cells (cumulus-oocyte expansion; C-OE) was established through the generation of PTGS2 and PTGER2 null-mutant mice. A critical role for PGE2 in primate ovulation is supported by evidence that intrafollicular injection of indomethacin in rhesus monkeys suppressed follicle rupture, whereas co-injection of PGE2 with indomethacin resulted in ovulation. First, controlled ovulation protocols were performed in adult, female rhesus monkeys to analyze the mRNA levels for genes encoding PGE2 synthesis and signaling components in the naturally selected pre-ovulatory follicle at different times after the ovulatory hCG stimulus (0, 12, 24, 36 h pre-ovulation; 36 h post-ovulation, n = 3-4/time point). Second, controlled ovarian stimulation cycles were utilized to obtain multiple cumulus-oocyte complexes (COCs) from rhesus monkeys to evaluate the role of PGE2 in C-OE in vitro (n = 3-4 animals/treatment; ≥3 COCs/animal/treatment). Third, adult cycling female cynomolgus macaques were randomly assigned (n = 10/group) to vehicle (control) or PTGER2 antagonist (BAY06) groups to perform a contraceptive trial. After the first treatment cycle, a male of proven fertility was introduced into each group and they remained housed together for the duration of the 5-month contraceptive trial that was followed by a post-treatment reversibility trial. Quantitative real-time PCR, COC culture and expansion, immunofluorescence/confocal microscopy, enzyme immunoassay, contraceptive trial, ultrasonography, complete blood counts, serum biochemistry tests and blood lipid profiles. Several mRNAs encoding proteins involved in PGE2 synthesis, metabolism and signaling increase (P < 0.05) in the periovulatory follicle after administration of an ovulatory hCG bolus. PGE2 signaling through PTGER2 induces cumulus cell expansion and production of hyaluronic acid, which are critical events for fertilization. Moreover, chronic administration of a selective PTGER2 antagonist resulted in a significant (P < 0.05 versus vehicle-treated controls) contraceptive effect
doi_str_mv 10.1093/humrep/deu083
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4059334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24781425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-378c9834118e9a4c108399facfce6276056f01ef1f7fc84231756a737f842e5e3</originalsourceid><addsrcrecordid>eNpVUV1PwyAUJUbj5vTRV8MfqINCKX0xWZb5kSzxRZ8bpJcN09IK7Yz_Xprqok_33MPhXLgHoWtKbikp2HI_NB66ZQUDkewEzSkXJElZRk7RnKRCJpQKOkMXIbwTEqEU52iW8lxSnmZz9LXCnW9Dr3a1cpV1eJNiDxq6vvVYuci3zoY-iuAArg8j2DnltIWAq8Fbt8NqJHVtndWqxrp1vVejgz0A7r2N3Kft99hAo2rAjdLqY4Bwic6MqgNc_dQFer3fvKwfk-3zw9N6tU00k3mfsFzqQjJOqYRCcU3jN4vCKG00iDQXJBOGUDDU5EZLnjKaZ0LlLDexgQzYAt1Nvt3w1kClYXxeXXbeNsp_la2y5f8TZ_flrj2UnGQFYzwaJJOBjosKHszxLiXlmEE5ZVBOGUT9zd-BR_Xv0tk3H2GI8w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Peluffo, M C ; Stanley, J ; Braeuer, N ; Rotgeri, A ; Fritzemeier, K-H ; Fuhrmann, U ; Buchmann, B ; Adevai, T ; Murphy, M J ; Zelinski, M B ; Lindenthal, B ; Hennebold, J D ; Stouffer, R L</creator><creatorcontrib>Peluffo, M C ; Stanley, J ; Braeuer, N ; Rotgeri, A ; Fritzemeier, K-H ; Fuhrmann, U ; Buchmann, B ; Adevai, T ; Murphy, M J ; Zelinski, M B ; Lindenthal, B ; Hennebold, J D ; Stouffer, R L</creatorcontrib><description>Can administration of a prostaglandin (PG) E2 receptor 2 (PTGER2) antagonist prevent pregnancy in adult female monkeys by blocking periovulatory events in the follicle without altering menstrual cyclicity or general health? This is the first study to demonstrate that a PTGER2 antagonist can serve as an effective non-hormonal contraceptive in primates. The requirement for PGE2 in ovulation and the release of an oocyte surrounded by expanded cumulus cells (cumulus-oocyte expansion; C-OE) was established through the generation of PTGS2 and PTGER2 null-mutant mice. A critical role for PGE2 in primate ovulation is supported by evidence that intrafollicular injection of indomethacin in rhesus monkeys suppressed follicle rupture, whereas co-injection of PGE2 with indomethacin resulted in ovulation. First, controlled ovulation protocols were performed in adult, female rhesus monkeys to analyze the mRNA levels for genes encoding PGE2 synthesis and signaling components in the naturally selected pre-ovulatory follicle at different times after the ovulatory hCG stimulus (0, 12, 24, 36 h pre-ovulation; 36 h post-ovulation, n = 3-4/time point). Second, controlled ovarian stimulation cycles were utilized to obtain multiple cumulus-oocyte complexes (COCs) from rhesus monkeys to evaluate the role of PGE2 in C-OE in vitro (n = 3-4 animals/treatment; ≥3 COCs/animal/treatment). Third, adult cycling female cynomolgus macaques were randomly assigned (n = 10/group) to vehicle (control) or PTGER2 antagonist (BAY06) groups to perform a contraceptive trial. After the first treatment cycle, a male of proven fertility was introduced into each group and they remained housed together for the duration of the 5-month contraceptive trial that was followed by a post-treatment reversibility trial. Quantitative real-time PCR, COC culture and expansion, immunofluorescence/confocal microscopy, enzyme immunoassay, contraceptive trial, ultrasonography, complete blood counts, serum biochemistry tests and blood lipid profiles. Several mRNAs encoding proteins involved in PGE2 synthesis, metabolism and signaling increase (P &lt; 0.05) in the periovulatory follicle after administration of an ovulatory hCG bolus. PGE2 signaling through PTGER2 induces cumulus cell expansion and production of hyaluronic acid, which are critical events for fertilization. Moreover, chronic administration of a selective PTGER2 antagonist resulted in a significant (P &lt; 0.05 versus vehicle-treated controls) contraceptive effect without altering steroid hormone patterns or menstrual cyclicity during a 5-months contraceptive trial. Fertility recovered as early as 1 month after ending treatment. This is a proof-of-concept study in a non-human primate model. Further investigations are warranted to elucidate the mechanism(s) of PTGER2 antagonist action in the primate ovary. Although PTGER2 antagonist treatment did not produce any obvious undesirable effects, improvements in the mode of administration, as well as the efficacy of these compounds, are necessary to consider such a contraceptive for women. Monitoring as well as improving the efficacy and safety of female contraceptives is an important public health activity. Even though hormonal contraceptives are effective for women, concerns remain regarding their side-effects and long-term use because of the widespread actions of such steroidal products in many tissues. Moreover, some women cannot take hormones for medical reasons. Thus, development of non-hormonal contraceptives for women is warranted. Supported by Bayer HealthCare Pharmaceuticals, The Eunice Kennedy Shriver NICHD Contraceptive Development and Research Center (U54 HD055744), NIH Office of the Director (Oregon National Primate Research Center P51 OD011092), and a Lalor Foundation Postdoctoral Basic Research Fellowship (MCP). The use of the Leica confocal was supported by grant number S10RR024585. Some of the authors (N.B., A.R., K.-H.F., U.F., B.B. and B.L.) are employees of Bayer Healthcare Pharma.</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/deu083</identifier><identifier>PMID: 24781425</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Animals ; Contraception - methods ; Contraceptive Agents - therapeutic use ; Female ; Gene Expression Regulation ; Indomethacin - therapeutic use ; Macaca ; Macaca fascicularis ; Oocytes - drug effects ; Original ; Ovarian Follicle - drug effects ; Ovary - drug effects ; Ovulation - drug effects ; Pregnancy ; Pregnancy, Animal ; Receptors, Prostaglandin E - antagonists &amp; inhibitors ; RNA, Messenger - metabolism ; Time Factors</subject><ispartof>Human reproduction (Oxford), 2014-07, Vol.29 (7), p.1400-1412</ispartof><rights>The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-378c9834118e9a4c108399facfce6276056f01ef1f7fc84231756a737f842e5e3</citedby><cites>FETCH-LOGICAL-c387t-378c9834118e9a4c108399facfce6276056f01ef1f7fc84231756a737f842e5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24781425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peluffo, M C</creatorcontrib><creatorcontrib>Stanley, J</creatorcontrib><creatorcontrib>Braeuer, N</creatorcontrib><creatorcontrib>Rotgeri, A</creatorcontrib><creatorcontrib>Fritzemeier, K-H</creatorcontrib><creatorcontrib>Fuhrmann, U</creatorcontrib><creatorcontrib>Buchmann, B</creatorcontrib><creatorcontrib>Adevai, T</creatorcontrib><creatorcontrib>Murphy, M J</creatorcontrib><creatorcontrib>Zelinski, M B</creatorcontrib><creatorcontrib>Lindenthal, B</creatorcontrib><creatorcontrib>Hennebold, J D</creatorcontrib><creatorcontrib>Stouffer, R L</creatorcontrib><title>A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>Can administration of a prostaglandin (PG) E2 receptor 2 (PTGER2) antagonist prevent pregnancy in adult female monkeys by blocking periovulatory events in the follicle without altering menstrual cyclicity or general health? This is the first study to demonstrate that a PTGER2 antagonist can serve as an effective non-hormonal contraceptive in primates. The requirement for PGE2 in ovulation and the release of an oocyte surrounded by expanded cumulus cells (cumulus-oocyte expansion; C-OE) was established through the generation of PTGS2 and PTGER2 null-mutant mice. A critical role for PGE2 in primate ovulation is supported by evidence that intrafollicular injection of indomethacin in rhesus monkeys suppressed follicle rupture, whereas co-injection of PGE2 with indomethacin resulted in ovulation. First, controlled ovulation protocols were performed in adult, female rhesus monkeys to analyze the mRNA levels for genes encoding PGE2 synthesis and signaling components in the naturally selected pre-ovulatory follicle at different times after the ovulatory hCG stimulus (0, 12, 24, 36 h pre-ovulation; 36 h post-ovulation, n = 3-4/time point). Second, controlled ovarian stimulation cycles were utilized to obtain multiple cumulus-oocyte complexes (COCs) from rhesus monkeys to evaluate the role of PGE2 in C-OE in vitro (n = 3-4 animals/treatment; ≥3 COCs/animal/treatment). Third, adult cycling female cynomolgus macaques were randomly assigned (n = 10/group) to vehicle (control) or PTGER2 antagonist (BAY06) groups to perform a contraceptive trial. After the first treatment cycle, a male of proven fertility was introduced into each group and they remained housed together for the duration of the 5-month contraceptive trial that was followed by a post-treatment reversibility trial. Quantitative real-time PCR, COC culture and expansion, immunofluorescence/confocal microscopy, enzyme immunoassay, contraceptive trial, ultrasonography, complete blood counts, serum biochemistry tests and blood lipid profiles. Several mRNAs encoding proteins involved in PGE2 synthesis, metabolism and signaling increase (P &lt; 0.05) in the periovulatory follicle after administration of an ovulatory hCG bolus. PGE2 signaling through PTGER2 induces cumulus cell expansion and production of hyaluronic acid, which are critical events for fertilization. Moreover, chronic administration of a selective PTGER2 antagonist resulted in a significant (P &lt; 0.05 versus vehicle-treated controls) contraceptive effect without altering steroid hormone patterns or menstrual cyclicity during a 5-months contraceptive trial. Fertility recovered as early as 1 month after ending treatment. This is a proof-of-concept study in a non-human primate model. Further investigations are warranted to elucidate the mechanism(s) of PTGER2 antagonist action in the primate ovary. Although PTGER2 antagonist treatment did not produce any obvious undesirable effects, improvements in the mode of administration, as well as the efficacy of these compounds, are necessary to consider such a contraceptive for women. Monitoring as well as improving the efficacy and safety of female contraceptives is an important public health activity. Even though hormonal contraceptives are effective for women, concerns remain regarding their side-effects and long-term use because of the widespread actions of such steroidal products in many tissues. Moreover, some women cannot take hormones for medical reasons. Thus, development of non-hormonal contraceptives for women is warranted. Supported by Bayer HealthCare Pharmaceuticals, The Eunice Kennedy Shriver NICHD Contraceptive Development and Research Center (U54 HD055744), NIH Office of the Director (Oregon National Primate Research Center P51 OD011092), and a Lalor Foundation Postdoctoral Basic Research Fellowship (MCP). The use of the Leica confocal was supported by grant number S10RR024585. Some of the authors (N.B., A.R., K.-H.F., U.F., B.B. and B.L.) are employees of Bayer Healthcare Pharma.</description><subject>Animals</subject><subject>Contraception - methods</subject><subject>Contraceptive Agents - therapeutic use</subject><subject>Female</subject><subject>Gene Expression Regulation</subject><subject>Indomethacin - therapeutic use</subject><subject>Macaca</subject><subject>Macaca fascicularis</subject><subject>Oocytes - drug effects</subject><subject>Original</subject><subject>Ovarian Follicle - drug effects</subject><subject>Ovary - drug effects</subject><subject>Ovulation - drug effects</subject><subject>Pregnancy</subject><subject>Pregnancy, Animal</subject><subject>Receptors, Prostaglandin E - antagonists &amp; inhibitors</subject><subject>RNA, Messenger - metabolism</subject><subject>Time Factors</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUV1PwyAUJUbj5vTRV8MfqINCKX0xWZb5kSzxRZ8bpJcN09IK7Yz_Xprqok_33MPhXLgHoWtKbikp2HI_NB66ZQUDkewEzSkXJElZRk7RnKRCJpQKOkMXIbwTEqEU52iW8lxSnmZz9LXCnW9Dr3a1cpV1eJNiDxq6vvVYuci3zoY-iuAArg8j2DnltIWAq8Fbt8NqJHVtndWqxrp1vVejgz0A7r2N3Kft99hAo2rAjdLqY4Bwic6MqgNc_dQFer3fvKwfk-3zw9N6tU00k3mfsFzqQjJOqYRCcU3jN4vCKG00iDQXJBOGUDDU5EZLnjKaZ0LlLDexgQzYAt1Nvt3w1kClYXxeXXbeNsp_la2y5f8TZ_flrj2UnGQFYzwaJJOBjosKHszxLiXlmEE5ZVBOGUT9zd-BR_Xv0tk3H2GI8w</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Peluffo, M C</creator><creator>Stanley, J</creator><creator>Braeuer, N</creator><creator>Rotgeri, A</creator><creator>Fritzemeier, K-H</creator><creator>Fuhrmann, U</creator><creator>Buchmann, B</creator><creator>Adevai, T</creator><creator>Murphy, M J</creator><creator>Zelinski, M B</creator><creator>Lindenthal, B</creator><creator>Hennebold, J D</creator><creator>Stouffer, R L</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques</title><author>Peluffo, M C ; Stanley, J ; Braeuer, N ; Rotgeri, A ; Fritzemeier, K-H ; Fuhrmann, U ; Buchmann, B ; Adevai, T ; Murphy, M J ; Zelinski, M B ; Lindenthal, B ; Hennebold, J D ; Stouffer, R L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-378c9834118e9a4c108399facfce6276056f01ef1f7fc84231756a737f842e5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Contraception - methods</topic><topic>Contraceptive Agents - therapeutic use</topic><topic>Female</topic><topic>Gene Expression Regulation</topic><topic>Indomethacin - therapeutic use</topic><topic>Macaca</topic><topic>Macaca fascicularis</topic><topic>Oocytes - drug effects</topic><topic>Original</topic><topic>Ovarian Follicle - drug effects</topic><topic>Ovary - drug effects</topic><topic>Ovulation - drug effects</topic><topic>Pregnancy</topic><topic>Pregnancy, Animal</topic><topic>Receptors, Prostaglandin E - antagonists &amp; inhibitors</topic><topic>RNA, Messenger - metabolism</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peluffo, M C</creatorcontrib><creatorcontrib>Stanley, J</creatorcontrib><creatorcontrib>Braeuer, N</creatorcontrib><creatorcontrib>Rotgeri, A</creatorcontrib><creatorcontrib>Fritzemeier, K-H</creatorcontrib><creatorcontrib>Fuhrmann, U</creatorcontrib><creatorcontrib>Buchmann, B</creatorcontrib><creatorcontrib>Adevai, T</creatorcontrib><creatorcontrib>Murphy, M J</creatorcontrib><creatorcontrib>Zelinski, M B</creatorcontrib><creatorcontrib>Lindenthal, B</creatorcontrib><creatorcontrib>Hennebold, J D</creatorcontrib><creatorcontrib>Stouffer, R L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peluffo, M C</au><au>Stanley, J</au><au>Braeuer, N</au><au>Rotgeri, A</au><au>Fritzemeier, K-H</au><au>Fuhrmann, U</au><au>Buchmann, B</au><au>Adevai, T</au><au>Murphy, M J</au><au>Zelinski, M B</au><au>Lindenthal, B</au><au>Hennebold, J D</au><au>Stouffer, R L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>29</volume><issue>7</issue><spage>1400</spage><epage>1412</epage><pages>1400-1412</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><abstract>Can administration of a prostaglandin (PG) E2 receptor 2 (PTGER2) antagonist prevent pregnancy in adult female monkeys by blocking periovulatory events in the follicle without altering menstrual cyclicity or general health? This is the first study to demonstrate that a PTGER2 antagonist can serve as an effective non-hormonal contraceptive in primates. The requirement for PGE2 in ovulation and the release of an oocyte surrounded by expanded cumulus cells (cumulus-oocyte expansion; C-OE) was established through the generation of PTGS2 and PTGER2 null-mutant mice. A critical role for PGE2 in primate ovulation is supported by evidence that intrafollicular injection of indomethacin in rhesus monkeys suppressed follicle rupture, whereas co-injection of PGE2 with indomethacin resulted in ovulation. First, controlled ovulation protocols were performed in adult, female rhesus monkeys to analyze the mRNA levels for genes encoding PGE2 synthesis and signaling components in the naturally selected pre-ovulatory follicle at different times after the ovulatory hCG stimulus (0, 12, 24, 36 h pre-ovulation; 36 h post-ovulation, n = 3-4/time point). Second, controlled ovarian stimulation cycles were utilized to obtain multiple cumulus-oocyte complexes (COCs) from rhesus monkeys to evaluate the role of PGE2 in C-OE in vitro (n = 3-4 animals/treatment; ≥3 COCs/animal/treatment). Third, adult cycling female cynomolgus macaques were randomly assigned (n = 10/group) to vehicle (control) or PTGER2 antagonist (BAY06) groups to perform a contraceptive trial. After the first treatment cycle, a male of proven fertility was introduced into each group and they remained housed together for the duration of the 5-month contraceptive trial that was followed by a post-treatment reversibility trial. Quantitative real-time PCR, COC culture and expansion, immunofluorescence/confocal microscopy, enzyme immunoassay, contraceptive trial, ultrasonography, complete blood counts, serum biochemistry tests and blood lipid profiles. Several mRNAs encoding proteins involved in PGE2 synthesis, metabolism and signaling increase (P &lt; 0.05) in the periovulatory follicle after administration of an ovulatory hCG bolus. PGE2 signaling through PTGER2 induces cumulus cell expansion and production of hyaluronic acid, which are critical events for fertilization. Moreover, chronic administration of a selective PTGER2 antagonist resulted in a significant (P &lt; 0.05 versus vehicle-treated controls) contraceptive effect without altering steroid hormone patterns or menstrual cyclicity during a 5-months contraceptive trial. Fertility recovered as early as 1 month after ending treatment. This is a proof-of-concept study in a non-human primate model. Further investigations are warranted to elucidate the mechanism(s) of PTGER2 antagonist action in the primate ovary. Although PTGER2 antagonist treatment did not produce any obvious undesirable effects, improvements in the mode of administration, as well as the efficacy of these compounds, are necessary to consider such a contraceptive for women. Monitoring as well as improving the efficacy and safety of female contraceptives is an important public health activity. Even though hormonal contraceptives are effective for women, concerns remain regarding their side-effects and long-term use because of the widespread actions of such steroidal products in many tissues. Moreover, some women cannot take hormones for medical reasons. Thus, development of non-hormonal contraceptives for women is warranted. Supported by Bayer HealthCare Pharmaceuticals, The Eunice Kennedy Shriver NICHD Contraceptive Development and Research Center (U54 HD055744), NIH Office of the Director (Oregon National Primate Research Center P51 OD011092), and a Lalor Foundation Postdoctoral Basic Research Fellowship (MCP). The use of the Leica confocal was supported by grant number S10RR024585. Some of the authors (N.B., A.R., K.-H.F., U.F., B.B. and B.L.) are employees of Bayer Healthcare Pharma.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>24781425</pmid><doi>10.1093/humrep/deu083</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0268-1161
ispartof Human reproduction (Oxford), 2014-07, Vol.29 (7), p.1400-1412
issn 0268-1161
1460-2350
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4059334
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Contraception - methods
Contraceptive Agents - therapeutic use
Female
Gene Expression Regulation
Indomethacin - therapeutic use
Macaca
Macaca fascicularis
Oocytes - drug effects
Original
Ovarian Follicle - drug effects
Ovary - drug effects
Ovulation - drug effects
Pregnancy
Pregnancy, Animal
Receptors, Prostaglandin E - antagonists & inhibitors
RNA, Messenger - metabolism
Time Factors
title A prostaglandin E2 receptor antagonist prevents pregnancies during a preclinical contraceptive trial with female macaques
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A06%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prostaglandin%20E2%20receptor%20antagonist%20prevents%20pregnancies%20during%20a%20preclinical%20contraceptive%20trial%20with%20female%20macaques&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Peluffo,%20M%20C&rft.date=2014-07-01&rft.volume=29&rft.issue=7&rft.spage=1400&rft.epage=1412&rft.pages=1400-1412&rft.issn=0268-1161&rft.eissn=1460-2350&rft_id=info:doi/10.1093/humrep/deu083&rft_dat=%3Cpubmed_cross%3E24781425%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24781425&rfr_iscdi=true